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survival (DFS) were used as main outcomes in these
transplantations.
Results: Thirteen patients including 7 boys and 6 girls with
mean age 5.33 years (range: 0.25-11) were detected through
the data registry bank. The mean donors' age was 61.77 years
(range: 45-75) and mean age difference was 56.44 years
(range: 36.5-73) [Table 1]. Regarding GVHD occurrence, 10
patients did experience acute GVHD [Table 1]. With median
follow-up of 16 months OS and DFS were 83% and 69%
respectively.
Conclusion: Although searching the extended family for
HLA-matched donors especially among grandparents seems
very uncommon, this can increase the chance of well-toler-
ated and success transplantation especially in regions where
consanguinity is common.
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Haploidentical donor is often the only source of graft for
most patients in developing countries due to lack of suitably
matched donors from international registries and the
prohibitive cost involved in the procurement process. We
conducted a pilot study with posttransplant cyclophospha-
mide and haploidentical PBSC graft. The donors selected
were either mother or NIMA mismatched siblings irre-
spective of NK cell alloreactivity. The conditioning protocol
was developed based on Johns Hopkins regimen of Fludar-
abine and low-dose Cyclophosphamide pre-transplant with
escalating doseMelphalan 70-140mg/m2 replacing 2 Gy TBI.
Post-transplant Cyclophosphamide was administered 72hrs
after infusion of the graft at 50 mg/kg twice at 24 hrs interval
followed by Cyclosporine and MMF.
8 patients (median age-16, 5-43) underwent Haplo-HCT; 5
patients with refractory AML had a median BM blast count of
50% (20-80%) having failed at least two lines of treatment.
Two patients had severe aplastic anemia and one had thal-
assemia. The ones with AML received high dose AraC and
mitoxantrone from day-14 to -12. The conditioning was
tolerated without any major non-hematological toxicity. The
median CD34 was 7.06 x 106/kg (range 5.05-11.06) and CD3
was 36 x 107/kg (range 8-79).
All patients engrafted with neutrophils > 500/ml on day +14
(range12-17) and platelet count > 20,000/ml on day +15
(range 9-38) with > 95% donor chimerism on day +30 with
morphological CR. None of the patients with leukemia
developed de-novo GVHD. Three relapsed between days
100-150 and two of them achieved a CR following a second
transplant from the same donor. Two patients in CR died of
multi-drug resistant gram-negative bacterial sepsis. All three
patients with non-malignant disease developed unexpected
alloreactivity. One patient with SAA developed severerefractory HLH on day +21 and the other a periengraftment
idiopathic pneumonitis. Both succumbed to their complica-
tions. Another patient with thalassemia developed severe
HLH on day 60 related to EBV, whilst on treatment for grade 3
acute GVHD. In multiply treated advanced leukemia, the
introduction of the PBSC graft without any immunosup-
pression for 72 hours probably allowed a strong GVL effect
and post-transplant cyclophosphamide was successful in
abrogating clinically signiﬁcant GVHD. In sharp contrast, all
the three patients with non-malignant disease experienced
early and unexpected alloreactivity with the same protocol.
We speculate that the lack of previous cytotoxic therapy
might have left them vulnerable to such alloreactivity
mediated by residual host APCs.
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Early relapse (within 120 days) of high risk acute leukemia
after any form of allogeneic HCT, augers a poor outcome. We
report our experience with 4 such patients who relapsed
within 120 days of undergoing a haploidentical PBSCTwith or
without posttransplant cyclophosphamide. None developed
GVHD even with prophylactic DLI. Three had relapsed
refractory AML at the time of the ﬁrst haploidentical HCT and
one was transplanted for high risk ALL. The marrow blast
count at the time of second transplant was 20-80%. The
patients were conditioned with Fludarabine or Cladribine
withmelphalan (70mg/m2) ororal busulfan (4mg/kg) anddid
not receive any GVHD prophylaxis. Cryopreserved PBSC graft
was infused with CD34+ cells varying between 2-3 x 106/kg.
All the patients engrafted within 14 days and all developed
grade 2-3 acute GVHD by day 10. GVHD was treated with
steroids and etanercept along with tacrolimus andMMF. One
patient succumbed early to multidrug resistant Klebsiella
sepsis on day 15. The BM on day 30 in the other 3 patients
showed 100 % donor chimerismwith MRD levels of less than
0.1% on ﬂow cytometry. At a short follow up of 90 days from
the second haploidentical HCT, two out of three patients are
alive in CR with tapering immunosuppresion and the other
was lost to follow up after 50 days. Our data shows that
a haploidentical graft can induce a potent enough GVL effect
to induce remission even in refractory leukemia. These ﬁnd-
ings highlight the fact that even if a patient with refractory
leukemia relapses early after an allogeneic HCT without
developing GVHD, they deserve a second graft from the same
donor with minimally toxic conditioning with the purpose of
inducing a GVHD/GVL effect.
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Objective: We have previously reported that an HLA 8 of 8
allele-matched unrelated donor (8/8 MUD) is superior to
a related donor with HLA-1 antigen mismatch in the graft-
versus-host (GVH) direction (RD/1AG-MM-GVH) in trans-
plantation for leukemia (Kanda J, et al. Blood 2012). However,
the risk of relapse during the unrelated donor coordination
period biases this comparison. Therefore, we performed
decision analysis of donor selection in allogeneic stem cell
transplantation for acute myeloid leukemia (AML) and acute
lymphoblastic leukemia (ALL) in ﬁrst remission (CR1); this
method can consider various factors including risk of relapse
during the donor coordination period and the decrease in
quality of life (QOL) as a result of chronic graft-versus-host
disease (GVHD).
Methods: The incidences of relapse during the coordination
period of 8/8MUD or RD/1AG-MM-GVH were estimated
using the data from published studies on chemotherapeutic
treatment for AML and ALL. Transition probabilities after
transplantation were estimated using the database of the
Transplant Registry Uniﬁed Management Program for the
Japan Society for Hematopoietic Cell Transplantation. The
expected 5-year survival probabilities with or without QOL
adjustments were estimated using TreeAgePro software.
One-way sensitivity analysis was performed by varying each
transition-probability value within its plausible range.
Results: In transplantation for AML-CR1, the expected 5-year
survival probability was higher on selection of 8/8MUD than
RD/1AG-MM-GVH (59% vs. 47%), and this superiority
remained unchanged by sensitivity analysis of various
factors, including the interval between achievement of CR1
and actually receiving transplantation. In transplantation for
ALL-CR1, the 5-year survival probability was higher on
selection of 8/8 MUD (48% vs. 43%). In one-way sensitivity
analysis, the 5-year survival probability was higher on
selection of RD/1AG-MM-GVH when the interval between
CR1 and 8/8 MUD transplantation was 7 months. However,
8/8 MUD was superior after QOL adjustments. If the 5-year
survival rate was increased by 3% (7% after QOL adjustment)
in transplantation using RD/1AG-MM-GVH, the merit of
selecting RD/1AG-MM-GVH outweighs that of 8/8 MUD.
Conclusions: 8/8MUDshouldbeprioritized in transplantation
for AML-CR1. In transplantation for ALL-CR1, RD/1AG-MM-
GVHshould beprioritized onlywhen the interval between CR1
and 8/8 MUD transplantation is expected to be long. However,
MUD should be prioritized if QOL is considered.476
Missing KIR-Ligands in Single Mismatched Unrelated
Hematopoietic Stem Cell Transplantation
Christine Zollikofer, Daniel Fürst, Hubert Schrezenmeier,
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Clinical Transfusion Medicine and Immunogenetics Ulm
gGmbH (IKT), Ulm, GermanyOccurrences of relapse and transplantation related mortality
(TRM) are major complications after allogeneic hematopoi-
etic stem cell transplantation (HSCT). In haploidentical
transplantation, mismatches for inhibitory killer cell immu-
noglobulin-like receptor (KIR)-ligand in GvHD direction have
been shown to be associated with lower rates of relapse.
To investigate a potential effect of NK alloreactivity as pre-
dicted by themissing ligandmodel in the setting of unrelated
transplantation, we investigated 496 patients transplanted
for malignant disorders with single HLA-B or HLA-C mis-
matched donors and T-cell-replete grafts. “Missing ligand”
was deﬁned as absence of a donor KIR ligand HLA-C group 1,2
or HLA-Bw4 allele in the patient in GvH-direction only or in
combined HvG/GvH direction. Overall survival (OS), disease
free survival (DFS), relapse, and treatment related mortality
(TRM)were assessed usingKaplan-Meier analysis, competing
risks regression and extended Cox regression models.
Out of the 496 transplantation pairs, 109 (22.0%) were iden-
tiﬁed as belonging to the “missing ligand”-group, the
remaining 387 (78.0%) were used as a control group. Univar-
iate and multivariate analysis did not show any differences
regarding OS or DFS between the two groups. Univariate
analysis showed no signiﬁcant difference regarding TRM
(31.6% vs. 21.1%, P¼ .13) anda signiﬁcant higher risk for relapse
(29.0% vs. 38.7%, P ¼ .048) in the “missing ligand” group.
Multivariate competing risks regressionshowednosigniﬁcant
difference for TRM (HR 0.76, CI 0.49-1.23, P ¼ .28) and a trend
towards increased rates of relapse (HR 1.49, CI 1.00e 2.20, P¼
.05) for the patients within the “missing ligand” group.
The results of this study do not conﬁrm previous results seen
in haploidentical HSCT. T-cell alloreactivity dominates over
NK cell alloreactivity and leads to a diminished reconstitu-
tion of KIR expression in T-cell-replete grafts and potentially
impaired “licensing” compared to T-cell depleted trans-
plantations. This effect could explain differences between
the haploidentical related and single mismatched unrelated
transplantation.
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Adoptive transfer of T cells directed to tumor-associated
antigens (TAAs) by transgenic expression of chimeric antigen
receptors (CARs) can produce tumor responses, even in
patients with resistant malignancies. However targeting
a single TAA may lead to selection of the nontargeted TAA
population, leading to tumor immune escape. To overcome
this limitation, we have targeted two distinct TAAs, MUC1
and PSCA, both commonly express in pancreatic cancer. We
ﬁrst constructed a CAR targeting MUC1, which coexpressed
a truncated form of CD19 (DCD19) as a selectable marker.
After retroviral transduction, primary T cells stably expressed
both transgenes (834% and 668%, CAR-MUC1 and DCD19,
respectively). CAR-MUC1 T cells were able to speciﬁcally kill
MUC1+ target cell lines, CAPAN1 and DU145, with no
recognition of MUC1- targets, 293T (355%, 234% and
32% speciﬁc lysis, respectively, 10:1 E:T). To further eval-
uate the longer term killing effects, we cultured theseMUC1+
